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Individual differences in schizophrenia
Edmund T. Rolls, Wenlian Lu, Lin Wan, Hao Yan, Chuanyue Wang, Fude Yang, Yunlong Tan, Lingjiang Li,
Chinese Schizophrenia Collaboration Group, Hao Yu, Peter F. Liddle, Lena Palaniyappan, Dai Zhang,
Weihua Yue and Jianfeng Feng

Background
Whether there are distinct subtypes of schizophrenia is an
important issue to advance understanding and treatment of
schizophrenia.
Aims
To understand and treat individuals with schizophrenia, the aim
was to advance understanding of differences between individuals,
whether there are discrete subtypes, and how first-episode
patients (FEP) may differ from multiple episode patients (MEP).
Method
These issues were analysed in 687 FEP and 1880 MEP with
schizophrenia using the Positive and Negative Syndrome
Scale for (PANSS) schizophrenia before and after antipsychotic
medication for 6 weeks.
Results
The seven Negative Symptoms were correlated with
each other and with P2 (conceptual disorganisation),

Previous research has indicated that schizophrenia is heterogeneous
in clinical symptoms and time course, suggesting the possibility of
identifying subtypes differing in cause and/or pathological mechanism.1 The identification of subtypes could facilitate investigation
of cause and mechanism, including the use of genetic and neuroscience approaches.2–5 Many approaches consider that there are
positive symptoms (including hallucinations and delusions), negative symptoms (including low mood, motivation, and emotion),
and cognitive symptoms, including poor attention.6–8 It has been
suggested that at least in chronic cases, the positive symptoms split
into two subgroups: reality distortion and disorganisation.7,9 Many
studies that have included a wider range of symptoms have found
evidence for five clusters of symptoms, namely, reality distortion,
disorganisation, negative symptoms, depression and excitation (reviewed by Peralta & Cuesta).10
In order to better understand and treat individuals with schizophrenia, the aims of the present investigation were to understand
differences between individuals with schizophrenia; whether there
are discrete subtypes of schizophrenia; how first-episode patients
(FEP) may differ from multiple episode patients (MEP) and how
medication influences the symptoms. Two approaches to delineating the heterogeneity of schizophrenia were taken. One approach
was an examination of the pattern of correlation between symptoms to identify underlying symptom communities (or dimensions), presumed to reflect specific pathological processes. Another
approach was an examination of the correlations between patients,
to identify communities of patients (subtypes) each characterised
by a symptom profile reflecting a particular combination of symptom dimensions. In the main text, we employ the standard and
well-established hierarchical clustering method using k-means.11
In the supplement, we present qualitatively similar results obtained
using a powerful community detection algorithm based on the

G13 (disturbance of volition), and G7 (motor retardation).
The main difference between individuals was in the cluster of
seven negative symptoms, which had a continuous unimodal
distribution. Medication decreased the PANSS scores for
all the symptoms, which were similar in the FEP and MEP
groups.
Conclusions
The negative symptoms are a major source of individual
differences, and there are potential implications for treatment.
Declaration of interests
L.P. received speaker fees from Otsuka Canada and
educational grant from Janssen Canada in 2017.
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concept of modularity described by Newman & Girvan,12 which
was also useful in providing an estimate of the optimum number
of communities.

Method
Participants and clinical assessment
Two samples comprising a total of 2567 patients with schizophrenia
were diagnosed according to DSM-IV criteria.13 The first sample included 687 FEP and drug-naive patients with schizophrenia. The
second study sample included 1880 multi-episode patients (MEP)
with schizophrenia with average duration of illness 7.97 years. The
patients were recruited from in-patients from four research centres (the Sixth Hospital of Peking University, the Second Xiangya
Hospital of Central South University, Beijing Anding Hospital and
Beijing HuiLongGuan Hospital) with institutional approval of the
investigation and informed consent of the patients.
The symptoms were assessed by trained researchers with the
30-item Positive and Negative Syndrome Scale for schizophrenia
(PANSS).14 For reference, in PANSS, positive symptoms P1–P7 are
Items 1–7, the negative symptoms N1–N7 are Items 8–14 and the
general symptoms G1–G16 are Items 15–30. In the figures, unless
otherwise stated, the symptoms are presented in this order, 1–30,
with the symptoms listed in the legend to Fig. 1a. The PANSS was
measured first in each of these patients when they were not receiving drug treatment. Then the patients were provided with one out
of the seven randomly assigned drugs (risperidone, quetiapine,
perphenazine, olanzapine, haloperidol, aripiprazole and ziprasidone) for a 6-week treatment period, and then the PANSS scores
were measured again. This design with the same patients assessed
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before and after medication allowed measurement of the PANSS
when untreated, and also enabled the effects of the medication to
be assessed using exactly the same patients. Further details of the
patient populations and the medication used are provided in the
Data supplement.
Statistical analysis
The data consisted for the MEP group of 1880 patient×30 symptom matrix, and for the FEP group of a 687 patient×30 symptom
matrix, for the unmedicated pre-treatment state. Corresponding
matrices were available for the post-treatment state, providing the
symptoms in the same patients after 6 weeks of treatment. The
methods included calculating the symptom correlation matrix and
the population correlation matrix. We also examined whether there
were discrete populations of patients using the k-means clustering
method (performed on the population correlation matrix), and
then analysed the symptoms in the sub-populations that were detected. We also investigated the distributions of symptoms across
the patient sub-populations.
The data were analysed using the k-means cluster analysis
algorithms that are a well-accepted approach standardised for
availability within Matlab, using the distance measure based on
correlations. This analysis was complemented by a modern community detection method described in the Data supplement, which
has the advantage that it can automatically provide an indication
of the optimal number of subgroups or communities into which
to cluster the data.15,16 The k-means approach was the method used
for analysis described in the main text, because it is a well-known
and understood method for clustering data, and because one major
difference between the populations that was identified with this approach was in the negative symptoms which have a component that
has a unimodal continuous distribution, so we did not wish to rely
on a community detection method that might have difficulty if it
was forced to determine the number of communities into which
to divide the population if it contained at least in part a continuous
distribution. However, for comparison key results with the community detection method are provided in the Data supplement.

Results
Multi-episode group pre-treatment (MEP_Pre)
Figure 1a shows the MEP_Pre symptom correlation matrix. The
negative symptoms (8–14) form a clear cluster. Some correlation
between these negative symptoms and P2 (conceptual disorganisation), G11 (poor attention), G13 (disturbance of volition) and G16
(active social avoidance) are also evident in the symptom correlation matrix shown in Fig. 1a. The community detection method
indicated that the symptoms belong to four distinguishable communities (Fig. S1). Symptom community four included the majority
of the positive symptoms (P1 P4 P5 P6 P7) and general symptoms
(G8 G9 G12 G14). Symptom Community 1 included the majority of
the negative symptoms (N1 N2 N3 N4 N6) and general symptoms
(G7 G13 G16).
As shown in Fig. S2, the community detection algorithm indicated that the sample contained three distinguishable communities
of patients. The patient clusters generate by the three-cluster output
of the k-mean algorithm had distinct symptom profiles (Fig. 1b). In
the MEP_Pre sample, the sub-population labelled PN (positive and
high negative symptoms, 694 cases) had high values for the negative
symptoms (N1–N7=symptoms 8–14). The sub-population labelled
Pn (positive and intermediate negative symptoms, 535 cases) had
intermediate values for the negative symptoms. The sub-population

labelled P (positive and low negative symptoms, 651 cases) had
low values for the negative symptoms, especially N1 and N2. Little
else differed between these clusters, except that the PN cluster had
a higher value for P2 (conceptual disorganisation) and relatively
small values for P1 and P3–P6; whereas the P cluster had relatively
high scores on symptoms P1, P3–P7, G8 and G9.
These analyses provided evidence that the scores of the negative
symptoms were an important factor that was different between the
three populations detected with k-means, and equally by the community detection algorithm (see Data supplement Fig. S3). Furthermore, Fig. 1a shows that there are moderately high correlations
between the seven negative symptoms, N1–N7 (Symptoms 8–14).
To investigate how the negative symptoms were distributed across
the population of MEP patients, the population × symptom data
matrix was sorted by the mean value of symptoms N1–N7. The result shown in Fig. 2a indicates that there is a graded distribution of
the negative symptoms across the population of 1880 MEP patients,
with patients at one end of the distribution having scores close to 1
(the minimum score possible) and at the other end close to 7 (the
maximum score possible). (In a control analysis, it was found that
this does not apply to the positive symptoms, which are not continuously graded throughout the range between scores of 1 and 7 as
are the negative symptoms shown in Fig. 2a.)
Further evidence was then sought of whether the distribution
of the mean score for the seven negative symptoms was continuous
and unimodal. Figure 2b and c show that the distribution of the
mean of the average of the negative symptom scores in the MEP_
Pre group has a unimodal distribution, in one dimension, rather
than a bimodal or multimodal distribution. Thus the most important way in which the three sub-populations of MEP–Pre patients
differed was in the negative symptom scores, which are continuously distributed from 1 to 7.
Multi-episode group post-treatment (MEP_Post)
The MEP_Post symptom correlation matrix showed, similarly
to the MEP_Pre condition illustrated in Fig. 1a, that the negative
symptoms (8–14) form a clear cluster (Fig. S5). Three sub-population clusters were again found by the community detection algorithm and the three clusters in the MEP_Post dataset that were
detected with the k-means algorithm which had 631 patients in the
PN cluster, 643 in the Pn cluster and 606 in the P cluster.
Figure 1c shows the average symptom values in the three patient clusters for the MEP_Post group. The group labelled PN (positive and high negative symptoms) had high values for the negative
symptoms (N1–N7=symptoms 8–14). The group labelled Pn (positive and intermediate negative symptoms) had intermediate values
for the negative symptoms. The group labelled P (positive and low
negative symptoms) had low values for the negative symptoms and
relatively low values also for the positive symptoms. It is notable
that the scores on all or most of the symptoms have been decreased
by the medication (Fig. 4d). Just as in the MEP_Pre condition, a
continuously graded distribution of the negative symptoms across
the population of 1880 MEP_Post patients was found, with patients
at one end of the distribution having scores close to 1 (the minimum score possible) and at the other end close to 7 (the maximum
score possible).
First-episode group pre-treatment (FEP_Pre)
Figure 3a shows the FEP_Pre symptom correlation matrix. The negative symptoms (8–14) form a clear cluster.
The community detection algorithm detected three clusters or
sub-populations of patients, and Fig. 3b shows the average symptom values in the three patient clusters for the FEP_Pre group from
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Fig. 1. (a) MEP_Pre symptom correlation matrix. The colour bar indicates the value of the Pearson correlation. In PANSS (14), P1–P7 are Symptoms
1–7, N1–N7 are Symptoms 8–14 and G1–G16 are Symptoms 15–30. The values for each score are 1–7. The symptoms are as follows: Delusions (P1),
Conceptual disorganisation (P2), Hallucinations (P3), Hyperactivity (P4), Grandiosity (P5), Suspiciousness/persecution (P6), Hostility (P7), Blunted affect
(N1), Emotional withdrawal (N2), Poor rapport (N3), Passive/apathetic social withdrawal (N4), Difficulty in abstract thinking (N5), Lack of spontaneity
and flow of conversation (N6), Stereotyped thinking (N7), Somatic concern (G1), Anxiety (G2), Guilt feelings (G3), Tension (G4), Mannerisms and
posturing (G5), Depression (G6), Motor retardation (G7), Uncooperativeness (G8), Unusual thought content (G9), Disorientation (G10), Poor attention
(G11), Lack of judgment and insight (G12), Disturbance of volition (G13), Poor impulse control (G14), Preoccupation (G15) and Active social avoidance
(G16). (b) MEP_Pre average symptom values in the three patient clusters detected by k-means. (c) MEP_Post average symptom values in the three
patient clusters detected by k-means.

the k-means analysis. The group labelled PN (positive and high
negative symptoms) had high values for the negative symptoms
(N1–N7=symptoms 8–14). The group labelled Pn (positive and
intermediate negative symptoms) had intermediate values for the
negative symptoms. The group labelled P (positive and low negative symptoms) had low values for the negative symptoms. Little
else differed between these clusters, except that the PN cluster has
a smaller value for P1 (delusions) and P3 (hallucinatory behaviour)
(Symptoms 1 and 3) and has higher scores for Symptoms 27–30
(G13–G16). The three clusters contained 228, 233 and 226 patients,
respectively. The symptom profiles of the groups detected by the
k-means algorithm (Fig. 3b) are very similar to the profiles of the
corresponding groups detected by the community detection algorithm (Figs. S9 and S10).

Figure 3a shows that there are moderately high correlations between the seven negative symptoms, N1–N7 (Symptoms 8–14). To
investigate how the negative symptoms were distributed across the
population of FEP patients, the population × symptom data matrix was sorted by the mean value of Symptoms N1–N7. The result
shown in Fig. 4a indicates that there is a graded distribution of the
negative symptoms across the population of 687 FEP_Pre patients,
with patients at one end of the distribution having scores close to 1
(the minimum score possible) and at the other end close to 7 (the
maximum score possible).
Figure 4b and c shows that the distribution of the mean of the
average of the negative symptom scores in the FEP_Pre group has
a unimodal distribution, in one dimension, rather than a bimodal
or multimodal distribution. Thus the most important way in which
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Fig. 2. (a) MEP_Pre group sorted by the average value of the negative symptoms, N1–N7 (Symptoms 8–14). The colour bar on the right shows the
PANSS score in the range 1–7. (b) The average score for Symptoms N1–N7 shown sorted by its value in each member of the MEP_Pre population
(green). The red plot shows the value for N1. (c) A histogram of the average score for Symptoms N1–N7 in the MEP_Pre group.

the three sub-populations of FEP_Pre patients differed was in
the negative symptom scores, which are continuously distributed
from 1 to 7.
First-episode group post-treatment (FEP_Post)
The FEP_Post symptom correlation matrix showed, similarly to the
FEP_Pre condition illustrated in Fig. 3a, that the negative symptoms (8–14) form a clear cluster (Fig. S12). Three sub-population
clusters were again found by the community detection algorithm
(Fig. S13), and the three clusters in the FEP_Post dataset that were
detected with the k-means algorithm had 288 patients in the PN
cluster, 221 in the Pn cluster and 178 in the P cluster.
Figure 3c shows the average symptom values in the three patient clusters for the FEP_Post group. The group labelled PN (positive and high negative symptoms) had high values for the negative
symptoms (N1–N7=symptoms 8–14). The group labelled Pn (yellow) had high scores for P1–P7 and intermediate values for the negative symptoms. The group labelled P had low values for the negative

and positive symptoms. It is notable that the scores on all or most of
the symptoms have been decreased by the medication (Fig. 4e). Just
as in the FEP_Pre condition, a continuously graded distribution of
the negative symptoms across the population of 687 FEP_Post patients was found, with patients at one end of the distribution having
scores close to 1 (the minimum score possible) and at the other end
close to 7 (the maximum score possible).
Effects of treatment on the PANSS scores
The effects of treatment with antipsychotic drugs on the PANSS
symptom scores for the MEP and FEP groups are shown in Fig.
4d and e. Interestingly, the treatment reduced almost all the
symptoms (with smaller effects for those close to baseline). The
effects on the symptoms were highly similar in the MEP and
FEP groups. Moreover, the reductions in the scores of the negative symptoms for the different sub-populations PN, Pn and P
produced by the medication were similar (making allowance for
the fact that the pre-treatment value was different in the three
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Fig. 3. (a) FEP_Pre symptom correlation matrix. The colour bar indicates the value of the Pearson correlation. In PANSS (14), P1–P7 are Symptoms
1–7, N1–N7 are Symptoms 8–14 and G1–G16 are Symptoms 15–30. The values for each score are 1–7. (b) FEP_Pre average symptom values in the
three patient clusters detected by k-means. (c) FEP_Post average symptom values in the three patient clusters detected by k-means.

sub-populations). The treatment consisted of one out of seven
randomly assigned drugs (risperidone, quetiapine, perphenazine, olanzapine, haloperidol, aripiprazole and ziprasidone) for
a 6-week treatment period. Further details on the effects of the
treatments are available from the authors on request and will be
provided elsewhere.16
Comparison of MEP and FEP groups
It is evident from Fig. 4d and e that in the pre-treatment condition,
the FEP and MEP groups had almost identical scores, and this is
confirmed by the explicit comparison shown in Fig. S19. It is evident from Fig. 4d and e that in the post-treatment condition, the
FEP and MEP groups had almost identical scores (though lower
than in the pre-treatment groups), and this is confirmed by the explicit comparison shown in Fig. S20.

Community detection results
The community detection algorithm fast_mo15 and its modified
form fast_mo_sgn16 applied to the population correlation matrix
produced very similar results as shown in the Data supplement
(Figs. S1–S14) to those described in the main text using k-means,
with the main difference that the numbers of patients in the different clusters or communities differed somewhat.
Factor analysis and multidimensional scaling on the
symptom correlation matrices
To provide further insight into how the different PANSS symptoms
are related to each other and how they separate from each other,
factor analyses and multidimensional scaling were performed
on the symptom correlation matrices, as described in the Data
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Fig. 4. (a) FEP_Pre group sorted by the average value of the negative symptoms, N1–N7 (Symptoms 8–14). The colour bar on the right shows the
PANSS score in the range 1–7. (b) The average score for Symptoms N1–N7 shown sorted by its value in each member of the FEP_Pre population
(green). The red plot shows the value for N1. (c) A histogram of the average score for Symptoms N1–N7 in the FEP_Pre group. (d and e) PANSS
symptom scores before and after treatment for (d) the MEP and (e) the FEP groups.
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supplement. These confirm that the major source of variation between individuals with schizophrenia is in the negative symptoms.

Discussion
The results of the analysis on the datasets with 687 FEP with
schizophrenia before treatment (FEP_Pre) and after treatment
(FEP_Post), and 1880 MEP before treatment (MEP_Pre) and after
treatment (MEP_Post), provide evidence that a major difference
between patients is the extent of the negative symptoms (Figs 1–4).
There is little evidence for very discrete populations, with instead
a gradation in the amount of the negative symptoms found across
the patient populations (Figs 1–4). Indeed, the distributions for the
mean of the negative symptoms N1–N7 are unimodal (Figs 2 and
4), so there is little support for discrete subtypes of schizophrenia,
on the basis of PANSS scores. Indeed, when the k-means and the
community detection algorithms did separate the patient populations into three groups, these groups were distinguished mainly by
the amount of the negative symptoms, as illustrated in Figs 1, 3, S3,
S4, S10 and S11. Figures 4d, e and S19 show that the PANSS symptoms are almost identical before treatment in the FEP and MEP
groups. Figures 4d, e and S20 show that the PANSS symptoms are
almost identical after treatment in the FEP and MEP groups. The
results shown in Fig. 4d and e show that medication decreases the
scores on essentially all PANSS symptom scores.
Our finding of a continuous unimodal distribution of negative
symptoms is consistent with many cross-sectional studies that have
described the heterogeneity of schizophrenia in terms of multiple
dimensions (reviewed by Peralta & Cuesta10). Our findings indicate
that the negative dimension plays a particularly important role in
differentiating patients, but do not provide evidence for discrete
subtypes of illness. However, our cross-sectional analyses do not
address the question of whether or not taking account of persistence of symptoms or treatment response might help identify discrete subtypes. Some previous studies that have taken account of the
tendency of symptoms to persist have identified a subtype of illness
designated deficit schizophrenia, characterised by persistent primary negative symptoms.17,18 Other studies, reviewed by Gillespie
et al,19 have concluded that treatment-resistant schizophrenia might
be categorically distinct from treatment-responsive schizophrenia.
Evidence from many treatment trials, reviewed by Barry et al,20
indicates that negative symptoms tend to be poorly responsive to
treatment. However, we found in our very large patient sample that
positive and negative symptoms reduced to a similar degree during
treatment. An issue that must be considered is the characteristics of
the patient sample, including selection criteria. It is illustrative to
compare our findings with Tollefson et al21 in a trial of olanzapine
compared with haloperidol in a large sample of approximately 2000
patients. (Although the focus of Tollefson et al study was on the
differences between responses to the two different antipsychotics,
those differences were small and for the purpose of this discussion
the differences between the antipsychotics is of limited relevance.)
Tollefson et al reported a reduction of six points in PANSS negative
symptom scores after 6 weeks of treatment with olanzapine and five
points after 6-weeks treatment with haloperidol. We found a reduction in PANSS negative symptom scores of 8.2 points in MEP and
8.3 points in FEP cases. It is possible that the fact that we excluded
cases with treatment resistant illness, whereas Tollefson et al did
not, contributed to the difference in the magnitude of the reduction
produced by antipsychotics. In addition, it is possible that social,
cultural or ethnic influences contributed to the greater reduction in
negative symptoms in our sample. We discuss this in greater detail
in the Data supplement in the ‘Social, cultural and ethnic influences
on response to treatment’ section.

It should be noted that we did not attempt to distinguish primary from secondary negative symptoms. Our finding of a significant correlation between the reduction in positive symptoms and
the reduction in negative symptoms raises the possibility that a
proportion of the negative symptoms reported in our study might
be secondary negative symptoms which are expected to decrease
during treatment. However, the results of an analysis of covariance
presented in the Data supplement show that the reduction in the
negative symptoms produced by the medication was in part independent of the reduction in the positive symptoms.
Furthermore, it is noteworthy that we found MEP and FEP
cases exhibited similar decreases in symptom severity during
6-weeks treatment. In contrast, other moderately large studies have
reported that FEP cases show a greater reduction in symptoms during treatment than MEP cases.22 In a longitudinal study extending
over the first 5 years of illness, Lieberman et al23 found that treatment response diminished with increasing number of relapses. It is
possible that the exclusion of participants with treatment-resistant
illness from our MEP sample contributed to our finding of a relatively large reduction of negative symptoms in MEP cases.
Further analyses showed the following
The negative symptoms (N1–N7) are moderately well correlated
with each other (Figs 1a and 3a). As demonstrated in the Data supplement, the results of applying the community detection algorithm
fast_mo_sgn to the symptoms showed that in the MEP and FEP
groups, both Pre- and Post-treatment, four symptom communities
were detected (with one minor exception). One community generally included most of the positive symptoms and another community included most of the negative symptoms (Figs S1, S5, S8
and S12). The analysis of symptom communities identified a community of symptoms dominated by anxiety and depression (G6) in
both FEP (Fig. S8) and MEP (Fig. S1) groups, both before and after
treatment. This is consistent with many studies that have reported a
depression syndrome in schizophrenia (see the review by Peralta &
Cuesta10). Furthermore, in the MEP_Pre cases, there was a community of symptoms reflecting disorganisation of thought and behaviour, together with cognitive symptoms such as poor attention,
resembling the disorganisation syndrome identified in symptomatic cases of chronic schizophrenia by Bilder et al 9 and Liddle.7 Further analysis of just the negative symptoms found that they could be
separated into three communities (N1, N2 and N4; N3 and N6; and
N5 and N7), and that these symptom communities were all similarly reduced by medication (Data supplement).
The results shown in Figs S19 and S20 show that the PANSS
symptoms are very similar between FEP and MEP groups without medication; and that the medication produces changes in both
groups which make the FEP_Post and MEP_Post groups very
similar after medication. These findings have major implications
for ‘staging’ hypotheses of schizophrenia. Any ‘staging’ hypothesis
would need to carefully factor out the effects of treatment for its results to be interpretable. It may be that very long-term patients with
schizophrenia do show symptom differences.5 But if so, that would
be related to the long-term nature of the disease not clearly evident
in the MEP and FEP groups described here.
K-means cluster analysis can be used to divide the patients into
2–4 sub-populations (with results for three sub-populations presented), which differ from each other mainly in the extent of the negative symptoms. Community detection analysis (using fast_mo_sgn)16
(modified from15) provides a very similar set of three sub-populations
of both the MEP and FEP group, though the numbers of patients in
each population are not identical. To the extent that the distribution
of the negative symptoms is in part continuous, the cluster/community detection may not imply that the sub-populations are very
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discrete. Instead, a continuous distribution of the negative symptom
scores from 1 to 7 across the population, as illustrated in Figs 1–4,
needs to be considered. One way to assess patients clinically might
be on the mean of the seven negative symptom PANSS scores, and
clinicians may wish to consider different treatments with the graded
distribution across the population in mind, with for example some
findings becoming available from Lu et al (in preparation).16
The finding that the main difference in the PANSS scores of different patients is in the extent of the negative symptoms is of considerable
interest. If a k-means analysis is performed using only the values of
the negative symptoms, then three population communities are found
which differ in the mean value of the negative symptoms (Figs S4 and
S11). This adds to the evidence that the values of the negative symptom
scores are an important factor in producing different sub-populations
or communities, and moreover that what distinguishes these communities includes a difference in the mean negative symptom scores.
Furthermore, the evidence in the Data supplement indicates that the
negative symptoms are independent of the positive and general symptoms (i.e. the correlations between these symptoms pre-treatment is
close to zero), so that there must be at least two partly independent
underlying brain processes that are involved.
Subtypes of schizophrenia are no longer included in DSM-5,
and this large study with unmedicated patients is of interest in that
context, for no highly discrete subtypes of patients were detected
in this study, but instead there was a continuous distribution of the
mean value of the negative symptoms in both the FEP and MEP
populations. The subtypes of symptoms illustrated in Figs S1, S5,
S8 and S12 do show how a modern community detection algorithm
clusters together different symptoms, with one symptom community including, for example, most of the positive symptoms, and a
second community including most of the negative symptoms.
The present investigation adds to previous analyses of subtypes of
schizophrenia (e.g.11,24–26) by using a very much larger sample of patients (2567) than in any previous investigation; by investigating the
symptoms in the same patients in both the unmedicated and medicated states; by comparing the symptoms in FEP and MEP and by
including a more powerful machine learning, community detection,
approach. This investigation differs from the analysis of a partly overlapping FEP patient population by Lu et al (in preparation)16 in that
we used here the same participants unmedicated and medicated to
understand the effects of the medication, which may produce clearer
results than comparing two different groups when unmedicated or
not; in the use of more classical clustering approaches to define how
the symptoms cluster and how the members of the population cluster; and in the emphasis on the continuous unimodal distribution of
the negative symptoms which differs between individuals, instead
of focusing on communities that are thought to be distinct because
they have been categorised separately by a community detection algorithm which looks for distinct communities.15
Apart from the large sample size in this study, a strength is that
the patients came from several centres, and that similar results were
obtained from the different centers.16 Another strength is assessment of the PANSS when unmedicated and after 6 weeks of medication in the same patients. Several limitations may be mentioned.
PANSS data were used to identify the communities in the present
investigation and the communities may become further refined
when further measures of differences between patients are included.
Some PANSS items, such as difficulty in abstract thinking (N5) and
poor attention (G11), include what may be different aspects of impoverished and disorganised thinking within single items, and separate assessment might lead to a richer categorisation.7,27 Further we

suggest that the classification of possible subtypes of schizophrenia
could be enhanced by also including information from functional
neuroimaging and from genetics.
In conclusion, in a very large sample of cases of schizophrenia,
we have demonstrated that variation in the negative symptoms is
an important aspect of the variation between patients with schizophrenia. The severity of the negative symptoms has a continuous
unimodal distribution supporting a dimensional description of
the heterogeneity of the illness, at least with respect to the negative
symptoms. Furthermore, in this sample from which treatment resistant cases were excluded, the severity of the negative symptoms
decreased substantially during 6 weeks of antipsychotic treatment
in both FEP and MEP cases.
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